Trial Profile
An Exploratory Study of Low-dose Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Gimeracil (Primary) ; Oteracil (Primary) ; Rivoceranib (Primary) ; Tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EASE
- 09 Dec 2019 Status changed from recruiting to completed.
- 28 Apr 2017 New trial record